Poor Prognosis in ES-SCLC

Typically, patients with ES-SCLC live less than 1 year after diagnosis1,2

Survival rates for patients with ES-SCLC treated with chemotherapy remain very low



Historically, median OS has been about 8 to 10 months for patients receiving first-line treatment for ES-SCLC2,3

Overall survival in ES-SCLC (n=313)2*


Overall survival in ES-SCLC graph

ES-SCLC needs first-line therapies that can extend survival for more patients4

ES-SCLC=extensive-stage small cell lung cancer; OS=overall survival.

*These data are based on an analysis of 1032 patients with small cell lung cancer (extensive stage, limited stage, or not classifiable) from the H. Lee Moffitt Cancer Center and Research Institute. Log-rank statistics were used to assess survival rates across two time periods: 1986 to 1999 (n=410) and 2000 to 2008 (n=622). Data presented here are for the ES-SCLC cohort (n=313), during the 2000 to 2008 time period.2


Rapid Relapse in ES-SCLC

Improving response to treatment remains critical in ES-SCLC3-7

Despite advances, outcomes remain poor with first-line chemotherapy



Progression-free survival has historically been ~6% at 12 months with etoposide + platinum-based chemotherapy8*

Almost all patients experience rapid relapse3,6,7

  • Despite an initial sensitivity to chemotherapy, patients with ES-SCLC relapse within months

Brain metastases contribute to a poor prognosis for patients with ES-SCLC9-12

  • ~10% of patients present with asymptomatic brain metastases

PFS=progression-free survival.

*Based on 1 study with 327 patients treated with EP between 2002 and 2007.8



References: 1. Foster NR, Renfro LA, Schild SE, et al. Multitrial evaluation of progression-free survival as a surrogate end point for overall survival in first-line extensive-stage small-cell lung cancer. J Thorac Oncol. 2015;10(7):1099-1106. 2. Schabath MB, Nguyen A, Wilson P, Sommerer KR, Thompson ZJ, Chiappori AA. Temporal trends from 1986 to 2008 in overall survival of small cell lung cancer patients. Lung Cancer. 2014;86(1):14-21. 3. Farago AF, Keane FK. Current standards for clinical management of small cell lung cancer. Transl Lung Cancer Res. 2018;7(1):69-79. 4. Rudin CM, Ismaila N, Hann CL, et al. Treatment of small-cell lung cancer: American Society of Clinical Oncology endorsement of the American College of Chest Physicians Guideline. J Clin Oncol. 2015;33(34):4106-4111. 5. Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30(14):1692-1698. 6. Pietanza MC, Averett Byers L, Minna JD, Rudin CM. Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res. 2015;21(10):2244-2255. 7. Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol. 2017;14(9):549-561. 8. Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27(15):2530-2535. 9. Wang S, Zimmermann S, Parikh K, Mansfield AS, Adjei AA. Current diagnosis and management of small-cell lung cancer. Mayo Clin Proc. 2019;94(8):1599-1622. 10. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive stage small-cell lung cancer. N Engl J Med. 2007;357:664-672. 11. Brueckl WM, Herbst L, Lechler A, et al. Predictive and prognostic factors in small cell lung carcinoma (SCLC)—analysis from routine clinical practice. Anticancer Res. 2006;26(6C):4825-4832. 12. Seute T, Leffers P, Wilmink JT, ten Velde GPM, Twijnstra A. Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy. J Clin Oncol. 2006;24(13):2079-2083.